Validation of the Lupus Low Disease Activity State (LLDAS) in the Asia Pacific Region

Launched by MONASH UNIVERSITY · May 1, 2017

Keywords

ClinConnect Summary

This clinical trial, called the Validation of the Lupus Low Disease Activity State (LLDAS) in the Asia Pacific Region, is studying how achieving a state of low disease activity can improve outcomes for patients with Systemic Lupus Erythematosus (SLE), a serious autoimmune disease that can damage various organs. The researchers will collect information from patients diagnosed with lupus to see if being in this low activity state helps protect them from further organ damage. This study is important because traditional measures of disease activity can be complex and many patients don’t reach full remission. By focusing on achieving a more attainable low activity state, the hope is to improve patient care.

To participate in this trial, patients must be at least 18 years old and have a confirmed diagnosis of lupus based on specific medical criteria. This includes those who are newly diagnosed or have had lupus for a long time. The trial is currently recruiting participants of all genders. Those who join can expect to provide information about their health over time, which will help the researchers understand the impact of low disease activity on their overall health and well-being.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • All patients have to meet either the 1997 American College of Rheumatology (ACR) Modified Classification Criteria for SLE, with at least four of the 11 items; or alternatively, fulfil the Systemic Lupus International Collaborating Clinics (SLICC) 2012 Classification Criteria, with at least four of the 17 items (at least one clinical and one immunological criterion) or with lupus nephritis in the presence of at least one immunological criteria. Patients can be either newly diagnosed or longstanding lupus patients.
• • All patients must be over the age of 18 and competent to provide written consent.
• Exclusion Criteria:
• • Patients less than 18 years of age and patients who are unable to consent are excluded from the study.